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ABSTRACT
The recent establishment of human embryonic stem cell lines has inspired a new revolution in
therapeutic treatments and cures for injuries or disease. Individual states have begun to
circumvent the lack of federal funding by independently raising monetary support for the
research. The patentee, The Wisconsin Alumni Research Foundation, has reminded those
hoping to benefit from the state funding that the Foundation will require royalties for the
commercial use of its patented technology. The loss of state taxpayer money to the patent
holder ignited a challenge on the patents themselves.
Interest groups requested a
reexamination of the stem cell patents and succeeded as the United States Patent &
Trademark Office has rejected all of the claims in each patent. This comment analyzes specific
issues raised in the reexamination and evaluates the righteousness of the royalties. The
comment proposes retention of patent law policy by continuing to reward innovation in order
to promote future invention and permitting a patentee to assess royalties for his efforts. The
comment also recommends an improved patent review process to lessen harassment of
patentees and strengthen the quality of patents issued.
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A Two-FRONT ASSAULT ON THE STEM CELL PATENTS
DILLON BEARDSLEY*

Patents are extremely important ....And so hopefully the field as a whole
can reach some sensible accommodation to WARF for the pioneering work
that they did do, but at the same time not stop the entire field from going
forward. It's a hard problem actually. 1
INTRODUCTION

Recently, a research group at Johns Hopkins University utilized transplanted
embryonic stem cell-derived nerve axons to partially restore neuromuscular activity
in paralyzed rats. 2 A Spanish research team has made advances in generating
insulin-producing pancreatic cells from embryonic stem cells, which may ultimately
aid diabetes sufferers. 3 Current advancements, such as these, have only begun to tap
into the benefits of human embryonic stem cell ("HESC") research. 4 However,
problems that may obstruct, and delay, the future of stem cell research have
surfaced. In particular, the scope of the stem cell patents and the licensing fees
levied by the patent holders are at issue.
This comment begins by introducing various issues resulting from stem cell
research along with the trials and tribulations scientists have faced in its infancy.
This comment then analyzes the issue of the stem cell patents' validity in light of the
recent claim rejections imposed by the United States Patent and Trademark Office
and whether the licensing agreements attached to the stem cell technology are
burdensome to research and therapeutic progress. Finally, this comment proposes
*J.D. Candidate, May 2008, The John Marshall Law School. B.S. Human Biology, University
of Wisconsin-Green Bay, December 1998. M.S. Biochemistry and Molecular Biology, Louisiana
State University-Health Sciences Center, 2005. The author would like to thank friends, family, The
John Marshall Law School, the RIPL staff, my editors, Tim Rechtien and Kevin Gualano, and,
especially, Susan.
1 Hearing Before the 1P Task Force of the Independent Citizens' Oversight Comm. to the
CaliforniaInstitute for Regenerative Medicine, 114-15 (2006), available at http://www.cirm.ca.gov/

transcripts/pdf/2006/04-27-06.pdf (statement of chariman, Dr. Edward Penhoet)
2

See generally Deepa Deshpande et al., Recovery from Paralysis in Adult Rats Using

Embryonic Stem Cells, 60 ANNALS OF NEUROLOGY 32 (2006) (describing the first report of the
anatomical and functional replacement of a motor neuron circuit within the adult mammalian host
partially rescuing the adult rat from paralysis).
3

See generally Pilar Vaca et al., Induction of Differentiation of Embryonic Stem Cells Into

Insulin -SecretingCells by Fetal Soluble Factors, 24 STEM CELLS 258 (2006) (elucidating techniques
that may be instrumental in engineering pancreatic beta cells from stem cells and demonstrating
normalization of blood glucose levels after transplantation of differentiated stem cells into diabetic
mice and hyperglycemia after graft removal).
4 Susanne Rust & Kathleen Gallagher, Stem Cell Work Crosses Boundaries.*UW Scientists
Aim to Make Wisconsin the Epicenter of a Medical Revolution, MILWAUKEE J. SENTINEL, April 23,
2006, at B1. "There isn't much known about these cells. So, we try things and see what happens.
And every time we do, we find something. We're seeing things people haven't seen before." Id.
(quoting Sean Palecek, associate professor of chemical and biological engineering, and stem cell
scientist).
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legislative reform and maintenance of patentee rights to satisfy both the incentive to
invent revolutionary science, such as stem cell technology, and the incentive to bring
helpful therapeutics to the masses.

I. BACKGROUND

This section elucidates the present struggle in stem cell science as ethical,
research, and patent interests try to find some accord. First, this section introduces
an overview of stem cell science. Second, this section explains the current policy in
the United States towards stem cell production and research. Finally, the section
discusses the State of California's response to the Federal government's policy on
stem cell funding and the State's current conflict with the stem cell patent holders.

A.

Human Embryonic Stem Cell Science

Human embryonic stem cells possess unique capabilities and characteristics
that have excited many in research and therapeutic treatment. 5 HESCs are derived
from human embryos at the most initial stages of development (approximately 5 days
after fertilization).6 The cells at this point exist undifferentiated, meaning they have
yet to commit to becoming a specific adult specialized cell line, i.e., muscle or nervous
cell lines. 7
Most importantly for scientists, HESCs can grow endlessly and
differentiate into any cell type of the human body. 8 These characteristics provide
thrilling potential for the study of life-threatening diseases such as cancer, diabetes,
Alzheimer's, Parkinson's, and HIV/AIDS via stem cell technology and/or creating
stem cell therapies. 9

B.

The CurrentPolicyin Human Stem Cell Research

Junying Yu & James A. Thomson, Embryonic Stem Cells, in NATIONAL INSTITUTES OF
HEALTH, REGENERATIVE MEDICINE 2006 1 (2006), available at http://stemcells.nih.gov/
staticresources/info/scireport/PDFs/Re generativeMedicine_2006.p df
(explaining
that
the
developmental potential of human ES cells in combination with the immortalization characteristics
of these cells will offer unending resources for beneficial research and therapy).

6 See generally James A. Thomson et al., Embryonic Stem Ce]] Lines Derived from Human
Blastocysts, 282 SCIENCE 1145 (1998) (detailing the process used by stem cell pioneer, Dr. James
Thomson, to derive stem cells from five-day-old human embryos produced via in vitro fertilization
(,,I")).
7 Yu & Thomson, supra note 5, at 1, 3 (noting that each of the cells of the inner cell mass
("ICM") are undifferentiated, i.e., they do not look or act like the specialized cells of the adult and
may later progress into nearly every type of cell line present in the adult human).
8 Id. at 2 fig.1.2 (illustrating that stem cells are pluripotent and give rise to cells from all three
embryonic germ layers, [1] the ectodermal line including: brain, spinal cord, nerve cells, hair, skin,
ears nose, and mouth; [2] the mesodermal line including: muscles, blood, blood vessels, and the
heart; and [3] the endodermal line including: the pancreas, liver, stomach, lungs, eggs, and sperm).
9 Id. at 7; CAL. CONST. art. XXXV, § 2 ("Recently medical science has discovered a new way to
attack chronic diseases and injuries.... [T]hrough the use of new regenerative medical therapies
including a special type of human embryonic cells, called stem cells.").
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HESCs in use today are most commonly derived from human embryos produced
by in vitro fertilization. 10 These embryos are usually created for infertile couples
hoping to have children of their own.11 However, thousands of the embryos are not
used and are necessarily discarded. 12 These previously discarded embryos became
the source of many HESCs used today. 13 Soon after taking office, President George
W. Bush tackled this ethically charged issue. 14 As a result, President Bush
established a ban on federal funding for any research utilizing HESCs created after
August 9, 2001.15 However, experimentation on the existing HESCs is now greatly
inhibited as the number of satisfactory HESC cell lines has dwindled. 16 Many
17
dispute Bush's policy and its great limitation to the future of stem cell research.
In response to the Bush policy, opposition has formed to persuade the
government to disencumber stem cell research. A group of past Nobel Prize winners

10 Yu & Thomson, supra note 5, at 3 (explaining creation of HESCs through the process of
oocytes and sperm combination and fertilization in a culture dish); JUDITH A. JOHNSON & ERIN
D.WILLIAMS, STEM CELL RESEARCH 1-2 (2005), available athttp://www.camradvocacy.org/resources/
CRSReportStemCellReseachAug05.pdf.

11David I. Hoffman et al., CryopreservedEmbryos in the United States and Their Availability
for Research, 79 FERTILITY & STERILITY 1063, 1066 (2003) (noting there are nearly 400,000 IVFproduced embryos in frozen storage in the United States alone, most of which will be used to treat
infertility).
12 Id. (observing that of the 400,000 IVF-produced embryos in storage, approximately 2.8% are
destined to be discarded).
13 Id,at 1063.
11Petition for Writ of Certiorari at *4, Doe v. Thompson, 126 S. Ct. 116 (2005) (No. 04-1642)
(noting the Bush administration already announced its intention to review the Government's stem
cell research policy early after taking over the office).
15 Press Release, The White House, Remarks by the President on Stem Cell Research, Aug. 9,
2001, http://www.whitehouse.gov/news/releases/2001/08/20010809- 1.html (last visited Apr. 19, 2007)
(announcing George W. Bush's policy that federal funds may be awarded for research using human
embryonic stem cells if the research meets certain criteria). The derivative [i.e., the extraction]
process (which begins with the destruction of the embryo) had to be initiated prior to 9:00 p.m. EDT
on August 9, 2001. Id. The stem cells must have been derived from an embryo that was created for
reproductive purposes and was no longer needed. Id. Informed consent must have been obtained for
the donation of the embryo and that donation must not have involved financial inducements. Id.
As a result of private research, more than 60 genetically diverse stem cell lines
already exist. ....
I have concluded that we should allow federal funds to be used
for research on these existing stem cell lines where the life and death decision has
already been made .... This allows us to explore the promise and potential of
stem cell research without crossing a fundamental moral line by providing
taxpayer funding that would sanction or encourage further destruction of human
embryos that have at least the potential for life.
Address to the Nation on Stem Cell Research, 2 PUB. PAPERS 953, 955 (Aug. 9, 2001) (quoting
President George W. Bush).
16 National Institutes of Health, Stem Cell Information: FAQs, http://stemcells.nih.
gov/info/faqs.asp#classes (last visited Apr. 19, 2007) (stating that the available number HESC cell
lines listed in the NIH Human Embryonic Stem Cell Registry is twenty-two); see also Claudia Kalb
& Debra Rosenberg, Stem Ce] Division, NEWSWEEK, Oct. 25, 2004, at 42 (noting that of the original
HESC lines, only a small amount were viable for research while others perished when thawed).
17

E.g.,

Peter Wallsten & Maura Reynolds, FristThrows Support Behind Stem Cell Resoa-reh,

L.A. TIMES, July 30, 2005 (noting that researchers should be given federal funding for research on
newer, more promising HESC lines).
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wrote a letter to the President urging a change in the funding policy.18 Popular
figures such as Michael J. Fox for Parkinson's Disease' 9 and Ronald Reagan, Jr. for
Alzheimer's Disease 2 have become active in the funding issue. Senator John Kerry,
during his 2004 bid for the presidency, vowed to ease the strict regulations against
the federal funding of HESC research. 21
On May 24, 2005, the House of
Representatives responded to the funding concerns by passing House Resolution 810,
"The Stem Cell Research Enhancement Act of 2005."22 This bill would have reversed

President Bush's ban by permitting the use of federal funds in stem cell research
under certain conditions. 23 However, President Bush remained
steadfast and
24
exercised the first veto of his administration to negate the bill.

Subsequently, the

House tried but failed to overcome the veto. 25 Undeterred by this legislative loss,
some states have continued their circumvention of the Bush policy by promoting stem
26
cell research through state-led funding initiatives.

18 See Gretchen Vogel, Nobel Laureates Lobby for Stem Cells, 291 SCIENCE 1683, 1683 (2001)
(stating on Feb. 22, 2001, eighty Nobel Prize winners signed a letter urging President Bush to allow
government-funded researchers to work on human pluripotent stem cells even though the Bush
Administration is under ethical pressure from anti-abortion groups to block federal funding for
research on human embryonic stem cells).
19Letter from Michael J. Fox to President George W. Bush (July 18, 2006) (on file with author)
(asking him to pass House Bill 810 and reverse the federal policy restricting funding of stem cell
research).
20 Robin Toner & Todd S. Purdum, On 2ndNight, Unity Is Theme For Democrats, N.Y. TIMES,
July 28, 2004, at Al. "[W]hatever else you do, come Nov. 2, I urge you, please, cast a vote for
embryonic stem cell research." Id. (quoting Ronald Reagan, Jr.).
21 Petition for Writ of Certiorari, supra note 14, at 10.
22 Stem Cell Research Enhancement Act of 2005, H.R. 810, 109th Cong. (2005).
23 Id. § 498D(b) (denoting the ethical requirements of human embryonic stem cells that shall be

eligible for use in any research conducted or supported by the Secretary).
(1) The stem cells were derived from human embryos that have been
donated from in vitro fertilization clinics, were created for the purposes of fertility
treatment, and were in excess of the clinical need of the individuals seeking such
treatment.
(2) Prior to the consideration of embryo donation and through consultation
with the individuals seeking fertility treatment, it was determined that the
embryos would never be implanted in a woman and would otherwise be discarded.
(3) The individuals seeking fertility treatment donated the embryos with
written informed consent and without receiving any financial or other
inducements to make the donation.
Id.
24 President's Message to the House of Representatives Returning Without Approval the Stem
Cell Research Enhancement Act of 2005, 42 WEEKLY COMP. PRES. DOc. 1365 (July 19, 2006). "Ifwe
are to find the right ways to advance ethical medical research, we must also be willing when
necessary to reject the wrong ways. For that reason, I must veto this bill." Id. (quoting President
George W. Bush).
25 152 CONG. REC. H5435 (daily ed. July 19, 2006) (noting that on July 19, 2006, H.R. 810
failed passage in the House over veto of President Bush by not garnering two-thirds of the vote (235
Yea-193 Nay)).
26 Tina Kelley, In Race Toward First Stem Cell Researeh Institute, New Jersey Stalls, N.Y.
TIMES, July 31, 2005, at 1; see also Betsy Morris, Fightingfor TheirLives, FORTUNE, Aug. 22, 2005,
at 48 (noting the other states in various stages of the legislative and initiative process); Associated
Press,
Wisconsin
Announces
Stem-Cell
Funding,
MSNBC,
Nov.
18,
2004,
http://www.msnbc.msn.com/id/6515491/ (last visited Feb. 11, 2007) (announcing Wisconsin Governor
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C. California'sResponse Via Proposition 71
California has responded against the current federal policy with the passage of
Proposition 71 that has earmarked an astounding $3 billion of publicly raised money
for stem cell research for the simultaneously created California Institute for
Regenerative Medicine ("CIRM").27
The passage of Proposition 71 in California
signaled further evidence of disagreement with the Bush Administration's stance and
further evidence that stem cell research requires public funding outside of the federal
government's control.28 Surprisingly, neither Proposition 71's supporters nor its
detractors made this issue into a pro-life vs. pro-choice battle. 29 Moreover, neither
30
side was opposed to stem cell research itself.
In spite of the progressive support for stem cell research, opponents have argued
against CIRM for the potential negative effects it may have on California.3 1 The
opponents feel it will increase the state of California's debt, shift money away from
other needy causes, and fill the pockets of the few corporations for which most of the
funds are destined.32 One prominent Californian regards Proposition 71 to be "the
wrong way to do the right thing."33 Specifically, the very companies standing to
benefit from the funding will undertake the institutional control of CIRM and CIRM

Jim Doyle's stem cell research funding initiative that will invest $750 million of public and private
money to build two research centers and support stem cell research).
27 CAL. CONST. art. XXXV, § 3 (clarifying the intent of the people of California in enacting this
measure). The policy authorizes an average of $295 million per year in bonds over a ten-year period
to fund stem cell research at newly established facilities at California's universities and medical
research facilities within the state. Id. The policy will maximize research funds by giving priority to
stem cell research with the greatest potential therapeutic benefit. Id. The policy will focus on
pluripotent stem cell and progenitor cell research that will overcome this area's deficiencies in
federal funding and will be unencumbered by limitations that would impede the research. Id.
28 CENTER FOR GENETICS AND SOCIETY, ASSESSMENT OF THE CALIFORNIA STEM CELL
RESEARCH AND CURES ACT (2004) http://www.genetics-and-society.org/policies/california/
assessment.html (last visited Apr. 19, 2007) (contrasting the $300 million stem cell research award
with the California Breast Cancer Research Program, the largest state-sponsored research effort in
the nation, that has granted scientists an average of $15 million a year since 1994 or twenty times
less than the level that Proposition 71 would provide for stem cell research); see Sean M. O'Connor,

Intellectual Property Rights and Stem Cell Research."Who Owns the Medical Breakthroughs., 39
NEW ENG. L. REV. 665, 676 (2005).
29 O'Connor, supra note 28, at 676 ("[N]either the official Rebuttal to Argument in Favor of
Proposition 71 nor the Argument Against Proposition 71 presented in the election materials was
there an opposition to stem cell research, embryonic or otherwise").
'30See Official Voter Information Guide, State of California Proposition 71, available at
http://vote2004.ss.ca.gov/voterguide/propositions/prop71-arguments.htm (last visited Apr. 19, 2007).
31 Id. (arguing other research and medical needs, already proven cost effective, should be
funded instead). The program is too costly and without adequate accountability or oversight. Id.
The proposition is a "blatant taxpayer rip-off' that will line the pockets of a few large corporations.
Id. Proposition 71 will give the proponents power over California "open meeting" laws and prohibit
the Governor and Legislature from exercising any oversight. Id.
32 Dan Gillmor, Some Thoughts on California's Propositions,SAN JOSE MERCURY NEWS, Oct.
24, 2004, at 1F ("The scope of this project is too massive for comfort given the state's shaky fiscal
position. And the benefits to taxpayers - who are likely to foot a large bill - are too abstract. The
whiff of corporate welfare is unmistakable.").
33 Posting of Mitch Kapor to Of By and For, http://www.ofbyandfor.org/node/view/830 (Oct. 25,
2004, 21:25 PST).
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funds. 34 CIRM is also exempt from public oversight and is allowed to implement its
35
own rules and policies, i.e., informed consent and protection for research subjects.
Furthermore, CIRM has set itself apart from the normal ground rules under which
research is conducted and commercialized, greatly increasing risk of ensuing
36
lawsuits and other unforeseen problems.
The opponents feel this lack of CIRM accountability leaves the researchers,
taxpayers, and businesses involved more vulnerable. 37 It is also not currently clear
how the state or its citizens would benefit from any subsequent profitable
technologies.38 Further, unresolved intellectual property issues, such as ownership of
39
future state-sponsored discoveries, often results in detrimental legal fights.
Additional concerns have also surfaced as a conflict between CIRM and the owners of
the stem cell patents. 40 In this matter, the patent holder's monopoly is balanced
opposite the desire of the powerful Californian corporations to enter unencumbered
into stem cell research. The taxpayers of California, who do not want state money
leaving the state, are also included in this conflict as patent royalty demands
41
threaten to reach into their own pockets.
'3 Id. (noting this as a conflict of interest and asking for a diversified oversight board, found in
similar research interests, to balance any conflicts); see Steve Johnson, Lawsuits Will Delay StemCell Research, SAN JOSE MERCURY NEWS, Aug. 2, 2005, at Al (stating that a current lawsuit claims
individuals in charge of CIRM have conflicts of interest that will impede the institution's ability to
fairly allocate taxpayer money).
35 Posting of Kapor, supra note 33.
Because there are significant health risks to women who agree to undergo the egg
retrieval necessary to conduct the embryo cloning, a much clearer and stricter
regulatory framework needs to be created before proceeding. The FDA has
received over 4000 reports of adverse drug events among women given the drug
Lupron to prepare them for the hyperstimulation that enables egg extraction.
This includes 325 hospitalizations and 25 deaths. Proposition 71 would create a
huge need and therefore huge pressure for women to donate eggs and raises the
possibility of exploitation as has happened in similar situations such as blood
donors.
Id.
3( Id. (noting that separating itself from normal operating rules for research institutions, it
may set itself up for unforeseen legal problems and result in hesitancy for those who may want to
enter the field); see also Carl T. Hall, Stem Cell Group Ready to Disburse Funds,; Institute, Critics
Near Agreement on ConfTicts, Meetings, SAN FRAN. CHRON., July 2, 2005, at BI (noting concerns
involving intellectual property and patent rights are yet to be resolved in addition to the other
finance and oversight issues of CIRM).
37 Posting of Kapor, supra note 33.
38 Id. (suggesting it would be far better to promote stem cell research either through Federal
activity (when favorable) or through the California legislature rather than through CIRM).
39Id.
40 California Stem Cell Report, http://californiastemeellreport.blogspot.com/2006/05/warf-tocirm-dont-mess-with-us.html (last visited Apr. 19, 2007) (referring to comments in California
concerning WARF's position on the Wisconsin patents). Andrew Cohn, government and public
relations manager for the organization, said, "These folks are absolutely going off the deep end. If it
wasn't for WiCell and for the University of Wisconsin, they wouldn't have anything to spend the $3
billion on in the first place." Id. The patent dispute between California and Wisconsin "promises to
be an intense fight" and 'WARF has proven over and over again that it will enforce its patents and
its contracts." Id.
41 Kathleen Gallagher, Stem Cell Patents Make Group a Target Challenge Points up State's
Role in Bringing Technology to Market, MILWAUKEE J. SENTINEL, July 23, 2006 at D1 (noting that
opponents hold the WARF patents harm both science and the California taxpayers).
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D. Stem Cell Patentsand the Conflict with California
The United States Patent and Trademark Office ("PTO") issued United States
Patent Nos. 5,843,780 ("the '708 patent"); 6,200,806 ("the '806 patent"); and 7,029,913
("the '913 patent") - all relating to embryonic stem ("ES") cells - to researcher Dr.
James A. Thomson who in turn assigned the patents to the Wisconsin Alumni
Research Foundation ("WARF").42 The '780 patent, issued on December 1, 1998,
contains claims directed to the broad category of all primate ES cells and a method
for isolating primate ES cells. 43

The '806 patent, issued on March 13, 2001, is

virtually identical to the '780 patent, except that the claims are directed specifically
to HESCs. 4 4 The claims of the '913 patent, issued April 18, 2006, are directed to

45
HESCs maintainable without the application of anti- differentiation factor.
WARF has openly shipped the stem cell lines it possesses to more than 300
research groups in twenty-one countries. 46 The cost for the cell lines for each group
was $5,000 until last fall when a National Institutes of Health subsidy helped lower
the price to $500 for academic researchers. 47 Additional costs totaling $125,000 or
more, plus annual fees, were assessed for private, non-academic labs. 48 Recently,
WARF has done away with these increased fees for private institutions in order to
encourage more research in this area deficient in federal funding. 49 However,
licensing fees are still mandatory when any product related to the stem cells becomes
commercialized. 50
These potential licensing costs have raised concern among
consumer advocates in matters of health and taxpayer money. 51 CIRM stipulated in

42 Primate Embryonic Stem Cells, U.S. Patent No. 5,843,780 (filed Jan. 18, 1996); Primate
Embryonic Stem Cells, U.S. Patent No. 6,200,806 (filed June 26, 1998); Primate Embryonic Stem
Cells, U.S. Patent No. 7,029,913 (filed Oct. 18, 2001).
43 '780 Patent col.21-22 (claiming a purified preparation of primate embryonic stem cells with
the ability to differentiate into all tissues derived from all three embryonic germ layers and a
method for isolating a primate embryonic stem cell line).
41'806 Patent col.21-22 (claiming identical preparations and methods to Patent No. 5,843,780
only for human embryonic stem cells).
45 '913 Patent col.21-22 (claiming HESCs which are capable of proliferation in in vitro culture
for over one year without the application of exogenous leukemia inhibitory factor).
46 David Wahlberg, Wisconsin, California in a Stem -Cell Skirmish, WIS. ST. J., June 18, 2006,
at Al.
47 Id.; see also WiCell, FAQs for Requesting Stem Cell Lines, http://www.wicell.org/index
.php?option=com content&task=blogcategory&id= 124&Itemid= 19 (last visited Apr. 19, 2007)
(noting WiCell entered into a contract with NIH and was named the National Stem Cell Bank
effective September 30, 2005). An agreement with the National Institutes of Health has allowed
WiCell Research Institute to offer HESCs to U.S. academic researchers at $500/line in an effort to
encourage more scientists to explore this new field of research. Id.
48 Wahlberg, supra note 46.
49 WiCell, Wisconsin Alumni Research Foundation Changes Stem Cell Policies to Encourage
Greater Collaboration,Jan. 22, 2007, available at http://www.wicell.org/index.php?option=com
content&task=view&id=166&Jtemid=170 (last visited Apr. 19, 2007) (explaining that private stem
cell research industry may now sponsor research performed at public or non-profit institutions).
50 WARF - Licensing Process, available at http://www.warf.org/industry/index.jsp?cid=l (last
visited Apr. 19, 2007).
51 Foundation for Taxpayer and Consumer Rights, Groups Challenge Stem Cell Patents That
Loot Taxpayer Funds and Force Research Overseas, http://www.consumerwatchdog.org/pr/?postId
=6572 (last visited Apr. 19, 2007) (describing the concern over health, hindrance of research, exodus
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its funding proposal that twenty-five percent of any royalties gained as a result of
52
research accomplished with its funding would return to the state of California.
However, WARF deems this research is commercialization of their product and
necessarily interjected its right to any royalties. 53 This could result in millions of
54
dollars of California taxpayer money leaving the state.
The transfer of California taxpayer money to Wisconsin is unacceptable to many
Californians; thus, the first salvo, Requests for Reexamination on each stem cell
patent, was submitted to the United States Patent Office. 55 Consumer advocates at
the Foundation for Taxpayer and Consumer Rights ("FTCR") and attorneys at the
Public Patent Foundation ("PUBPAT") asked the PTO to revoke the stem cell patents
on grounds they overreach and disclose claims covered by prior art.56 Additionally,
the concern of "suffocation of product" due to excessive layers of royalties is an issue
57
that must be scrutinized.
Proponents of CIRM have argued that the patents on stem cell science have been
a more serious hindrance to research on stem cells than President Bush's limitation
in federal funding in 2001.58 Thus, the patent-holder, WARF, faces a potentially long
assault attacking the validity of the stem cell patents. Further, arguments over the
"excessive" royalties are likely to persist. Perhaps a more sympathetic presidential
administration, growing public sentiment for disease cures, or the influx of money
and celebrity may find a way to circumvent WARF's control over stem cells.
of research, and wasted tax-payer money due to WARF requiring researchers, even tax-payer
funded, to pay royalties and seek approval before engaging in stem cell research).
52 CIRM Intellectual Property Policy at 19, available at http://www.cirm.ca.gov/
policies/pdf/IPPNPO.pdf (last visited Apr. 19, 2007) (noting that the 25% royalty is only enacted
when commercial proceeds exceed the threshold amount of $500,000).
53 CALIFORNIA STEM CELL REPORT, THE STEM CELL MEETING (2006) available at
http://californiastemcellreport.blogspot.com/2006 03 01 californiastemcellreport-archive.html (last
visited Apr. 19, 2007) (quoting Beth Donley, general counsel Wisconsin Alumni Research
Foundation '[I]f CIRM stipulates twenty-five percent royalties for California that requirement
amounts to commercialization. And that means WARF wants a payment from California.").
5 Id. (noting Beth Donley's remarks that licenses will start at around a bottom figure of
$75,000).
Peter Balbus, managing director at Pragmaxis LLC, of Glen Ellyn, Ill., estimated
Wisconsin could receive $200 million for $4 billion in stem cell product revenues. Id.
55 Foundation for Taxpayer and Consumer Rights, supra note 51 (explaining that the three
overreaching stem cell patents "should have never been issued in the first place").
56 Public Patent Foundation, http://www.pubpat.org/warfstemcellsfiled.htm (last visited Apr.
19, 2007) (listing the Requests for Reexamination of the stem cell patents, Nos. 5,843,780; 6,200,806;
and 7,029,913 and filing a letter of support by Dr. Jeanne F. Loring); see also Foundation for
Taxpayer and Consumer Rights, supra note 51 (arguing the patents on human embryonic stem cells
should not have been granted because the previous work of other scientists made the derivation of
human embryonic stem cells obvious and therefore unpatentable).
57 California Stem Cell Report, supra note 53 (citing Todd Lorenz's, chair, Life Sciences and
Health Care, Dorsey & Whitney L.L.P., concerns with Donley's account towards the issue of
'suffocation of product" defined as excessive layers of royalties of as much of twenty-five to thirty
percent that stifle commercialization of therapies).
58 Jennifer Washburn, Op-Ed., The LegalLock on Stem Cells, L.A. TIMES, April 12, 2006, at 13
(explaining that the stem cell patents cover all human embryonic stem cells and the method by
which they're made, thus exerting a dangerous monopoly that may counter the policy behind
patents, namely stimulation of innovation). The licensing fees charged by WARF are limiting the
researchers and companies able to participate in stem cell research. Id. (questioning the Patent
Office's grant of "building blocks" in science and explaining that the Thompson stem cell patents are
unreasonably broad since they cover all human embryonic stem cell lines).
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II. ANALYSIS
This section evaluates the issues raised by FTCR and PUBPAT in their fight to
invalidate the scope and royalties of the WARF patents. First, this section explains
the necessary hurdle FTCR and PUBPAT overcame to initiate its challenge on
patentability. Second, this section evaluates the patentability of the WARF patents
by scrutinizing the recent PTO rejection of the WARF patent claims. Finally, this
section introduces a secondary challenge introduced by FTCR and PUBPAT, namely
the imposition of excessive royalties, and investigates the merit of these accusations.

A. The PTO Finds a SubstantialNew Question of PatentabilityRaised by the
Reexamination
A third party may ask for reexamination and submit to the PTO "prior art
consisting of patents or printed publications that may bear on the patentability of
6
any claim of a patent."59 FTCR and PUBPAT initiated a request for reexamination
of WARF's stem cell patents by submitting references that include: (1) U.S. Patent
No. 5,166,065 ("the '065 patent);61 (2) a Robertson et al., publication ("Robertson
'83");62 (3) a second Robertson et al. publication ("Robertson '87");63 (4) a Piedrahita et
65
al. publication ("Piedrahita '90");64 and (5) a declaration of Dr. Jeanne F. Loring.
The PTO previously considered the Piedrahita '90 reference during the rejection of
the abandoned parent application of the '780 patent and, thus, there are limitations
on using this reference during the reexamination. 66 However, so long as the
substantial new question of patentability does not rely solely on this previously
considered Piedrahita reference, it may be used in conjunction with the newly
submitted prior art.67 The declaration of Dr. Loring was not considered a prior art
59 35 U.S.C. § 301 (2006) ("Any person at any time may cite to the Office in writing prior art
consisting of patents or printed publications which that person believes to have a bearing on the
patentability of any claim of a particular patent."); see also 35 U.S.C. § 302 (2006) ("The request
must set forth the pertinency and manner of applying cited prior art to every claim for which
reexamination is requested.").

60 PUBPAT, Groups Challenge Stem Cell Patents That Loot Taxpayer Funds and Force
Research Overseas: University of Wisconsin Affl]iate Claims Rights to All Embryonic Stem Cells
Used for Research, http://www.pubpat.org/warfstemcellsfiled.htm (last visited Apr. 19, 2007)).
61 In Vitro Propagation of Embryonic Stem Cells, U.S. Patent No. 5,166,065 (filed May 31,

1990).
62 ROBERTSON ET AL. I, TERATOCARCINOMAS AND EMBRYONIC STEM CELLS 647-83 (1983) (Cold
Spring Harbor Laboratory).
(33 ROBERTSON ET AL. II, TERATOCARCINOMAS AND EMBRYONIC STEM CELLS, A PRACTICAL
APPROACH 71-112 (1987).
(4

Piedrahita et al., On the Isolation of Embryonic Stem Cells.*Comparative Behavior of

Murine, Porcineand Ovine Embryos, 34 THERIOGENOLOGY, 879 (1990).
65 Declaration of Dr. Jeanne
F. Loring, http://www.pubpat.org/assets/files/warfstemcell/
LoringDeclarations.pdf (submitted to PTO July 17, 2006).
(3 PADMASHRI PONNALURI, UNITED STATES PATENT & TRADEMARK OFFICE, CONTROL No.
90/008,102 EX PARTE REEXAMINATION COMMUNICATION TRANSMITTAL FORM, Sept. 29, 2006,
http://www.pubpat.org/assets/files/warfstemcell/90008102- lgranted.pdf.
(7 In re Portola Packaging, 110 F.3d 786, 790 (Fed. Cir. 1997) (noting that Congress
intentionally limited the scope of reexamination to prior art not previously considered in order to
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patent or publication within the statutory requirement and was not used in the
68
examination.
The PTO held each request for ex parte reexamination, filed by FTCR and
PUBPAT, to raise a substantial new question of patentability. 69 The PTO concluded
each piece of prior art and the "old" Piedrahita reference describe technology so near
to the invention claimed by WARF that the art must be examined anew to determine
the validity, or obviousness, of the WARF patents.70 The references describe isolation
of ES cells, maintenance of these cells, and general aspirations of future research in
humans. 71 This PTO determination may not bode well for WARF as approximately
70% of reexaminations result in altered or cancelled claims. 7 2 However, closer
comparative analysis is necessary to determine if the PTO determination will subsist
and render the WARF patents obvious.

B. Are the Stem Cell Patents Obvious in Light of the PriorArt?
Upon further review by the PTO, the substantial new question of patentability
raised by FTCR and PUBPAT blossomed into a complete rejection of all WARF
claims as obvious or anticipated by the prior art.7 3 Now, WARF has sixty days to
respond to the remarks made by the PTO in the rejections.7 4 WARF's burden entails
a rebuttal of the points raised by the PTO with the intention of declaring that the
stem cell patents WARF possesses were nonobvious and not anticipated at the time
of their issue.
A patent claim is obvious, and thus invalid, when the differences between the
claimed invention and the prior art "are such that the subject matter as a whole
would have been obvious at the time the invention was made to a person having
76
ordinary skill in the art."75 This judgment proceeds on a claim-by-claim basis.
prohibit patentees from harassing reexamination requests); see 35 U.S.C. § 303(a) (2006); see also
Markman v. Lehman, 987 F. Supp. 25, 28 (D.C. Cir. 1997) (requiring new prior art or a combination
of new prior art with additional previously considered art as a standard for patent reexamination).
68 Ex Parto Reexamination Communication Transmittal Form, supra note 66.
9 Id.
70 Id.
71 Jd,
72 Kathleen Gallagher, Wisconsin Stem Cell Patents to Get Review, MILWAUKEE J. SENTINEL,

Oct. 4, 2006, at DI. "One or more of a patent's claims are changed 59% of the time when a third
party has requested a re-exam. All of the claims are confirmed 29% of the time and the patent is
cancelled 12% of the time." Id. (quoting U.S. Patent & Trademark spokesperson Brigid Quinn).
73
PONNALURI, supra note 66; BENNETT CELSA, UNITED STATES PATENT & TRADEMARK OFFICE,
CONTROL

No.

90/008,139

OFFICE

ACTION

http://www.pubpat.org/warfstemcell.htm

IN

Ex PARTE REEXAMINATION,

Mar.

30,

2007,

(rejecting Patent No. 6,200,806); GARY L. KUNZ, UNITED

STATES PATENT & TRADEMARK OFFICE, CONTROL NO. 95/000,154 OFFICE ACTION IN INTER PARTES

REEXAMINATION, Mar. 30, 2007, http://www.pubpat.org/warfstemcell.htm (rejecting Patent No.
7,029,913).
7437 C.F.R. 1.550(b) (2000) (the PTO must give at least thirty days for a response).
7535 U.S.C. § 103(a) (2006); Graham v. John Deere Co., 383 U.S. 1, 13 (1966).
76 35 U.S.C. § 282 (2006) ("Each claim of a patent (whether in independent, dependent, or
multiple dependent form) shall be presumed valid independently of the validity of other claims;
dependent or multiple dependent claims shall be presumed valid even though dependent upon an
invalid claim").
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Obviousness determinations rely on a factual examination of: (1) the scope and
content of the prior art; (2) the differences between the prior art and the claims of the
patent in question; (3) the level of skill in the art at the time of the invention; and (4)
the objective secondary factors of nonobviousness. 7 7 Until recently, the standard
articulated by the Court of Appeals for the Federal Circuit held that obviousness
based on the teachings of multiple prior art references must provide for some explicit
"suggestion, teaching, or motivation" that would have led a person of ordinary skill in
the art to combine the relevant prior art teachings in the manner claimed. 78 This
standard guarded against the often-misapplied hindsight-based obviousness
analysis. 79
The Supreme Court modified this obviousness analysis applied to
combinations of prior art references by disavowing the rigid Federal Circuit
standard.80
Nonetheless, the WARF patents should prevail under the current
obviousness inquiry.

1. The PriorArt
The '065 Patent teaches a method of isolating and maintaining mammalian ES
cells.81 The '065 Patent provides a list of mammalian representatives, including
humans, for which this invention would extend.8 2 Importantly, the '065 patent
specification does not denote any actual practice of the claimed method in an
application for isolating HESCs. 8 3 This invention also denotes the use of specialized
media for the purpose of modulating the survival and growth of the ES cells for up to
twenty weeks. 8 4 The Robertson '83 and Robertson '87 references cover like ground
(also in mouse ES cells) in the obviousness analysis, disclosing a "recipe" for
embryonic stem cell isolation and maintenance similar to the '065 Patent.8 5 The
previously considered Piedrahita '90 reference proclaims a method for isolating
77 Graham, 383 U.S. at 17-18 (solidifying the requirements of patentability with regards to
obviousness following difficulties in application after the enactment of the 1952 Patent Act).
78 See Teleflex, Inc. v. KSR Int'l Co., 119 F. App'x 282, 285 (Fed. Cir. 2005); see also In re
Kotzab, 217 F.3d 1365, 1371 (Fed. Cir. 2000) ("[P]articular findings must be made as to the reason
the skilled artisan, with no knowledge of the claimed invention, would have selected these
components for combination in the manner claimed."); In re Rouffet, 149 F.3d 1350, 1357 (Fed. Cir.
1998) ("In other words, the examiner must show reasons that the skilled artisan, confronted with
the same problems as the inventor and with no knowledge of the claimed invention, would select the
elements from the cited prior art references for combination in the manner claimed.").
79 In re Dembiczak, 175 F.3d 994, 998-99 (Fed. Cir. 1999) ("C]ritical step of casting the mind
back to the time of invention, to consider the thinking of one of ordinary skill in the art, guided only
by the prior art references and the then-accepted wisdom in the field."); see also Ruiz v. A.B. Chance
Co., 234 F.3d 654, 664-65 (Fed. Cir. 2000) (explaining that the temptation to engage in
impermissible hindsight is especially strong with seemingly simple mechanical inventions).
80 See KSR Int'l Co. v. Teleflex Inc., 550 U.S. - (2007).
81 See In Vitro Propagation of Embryonic Stem Cells, U.S. Patent 5,166,065 (filed May 31,
1990).
82 Id. at col.2 1.37-40 (listing humans, chickens, mice, fish, sheep, pigs, cattle, and goats).

83 Id.
84 Id. at col.10 (claiming a process for maintaining animal embryonic stem cells in vitro while
retaining their pluripotential phenotype that comprises culturing cells in a culture medium
containing leukaemia inhibitory factor ("LIF")).
85 See ROBERTSON ET AL. I, supranote 62; see ROBERTSON ET AL., supra note 63.
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embryonic stem cells attempted in mice, pigs, and sheep.8 6 Of note in the Piedrahita
reference were the conflicting results found using the same isolation and
87
maintenance methods on each animal species.
The PTO supplemented the prior art submitted by FTCR and PUBPAT with: (1)
U.S. Patent No. 5,453,357 ("the '357 patent")88; (2) U.S. Patent No. 5,690,926 ("the
'926 patent")89; and (3) the Bongso et al., publication ("Bongso").90 The '357 patent
discloses yet another isolation and maintenance of embryonic stem cells. 91 The '357
patent includes broad claims that encompass human cells even though HESC
isolation and maintenance was not specifically taught in the specification. 92 The '926
patent is a continuation-in-part
of the '357 patent and claims similar coverage under
"non-mouse" terminology. 93
The Bongso reference was considered during the
prosecution of the WARF patents but is now presented in a "new light" for the
obviousness analysis. 94 Bongso discloses an isolation technique for HESCs, but the
95
maintenance of these cells only lasted two passages.

2. The WARFPatents
By comparison, the '780 patent describes an advantageous embodiment wherein
primate ES cells are isolated and continue to proliferate in an undifferentiated state
for at least eleven months. 96 Further, the ES cell lines also have the ability to
differentiate into all tissues even after maintained in an undifferentiated state for
long periods of time. 97 Claim 11 of the '780 Patent also specifically claims a "cell
line."9 8 The '780 patent also notes "dramatic differences in primate and mouse
development limits the usefulness of mouse ES cells as a model of human
development." 99 Thus, the '780 patent utilized rhesus monkeys to isolate ES cells for
a more accurate model for human studies. 100 Last, the patent specifically notes that
no other primate (human or non-human) ES cell line exists, and others have failed to
86 Piedrahita et al., supra note 64 (comparing the efficiency of isolation and the characteristics
of embryo-derived cell lines from murine, porcine, and ovine embryos).
87 [d
88 Pluripotential Embryonic Cells and Methods of Making the Same, U.S. Patent No. 5,453,357
(filed Oct. 8, 1992).
89Pluripotential Embryonic Cells and Methods of Making the Same, U.S. Patent No. 5,690,926
(filed Mar. 25, 1994).
90 Ariff Bongso et al., Isolation and Culture of Inner Cell Mass Cells from Human Blastoeysts,
9 HUMAN REPRODUCTION 2110 (1994).

91 '357 Patent.
92 Id.
93'926 Patent col.15.
91 PONNALURI, supra note 66; CELSA, supra note 73.

95Bongso et al., supranote 90, at 2110.
96 Primate Embryonic Stem Cells, U.S. Patent No. 5,843,780 (filed Jan. 18, 1996).
97 Id. at col.4 (holding a qualification for the patent as continuous growth in cell culture for at

least one year).
98 Id. at col.22.
99Id. at col.2 (explaining that because humans are primates, and development is remarkably

similar among primates, primate ES cells lines will provide a better model for understanding
cellular differentiation in humans).
100 Id.at col.6.
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create permanent primate ES cell lines and demonstrate full differentiation
capabilities in isolated primate ES cells.11
The '806 patent of WARF is a divisional of the '780 patent. 10 2 The patent's
innovative extension is to human embryonic stem cell lines. 103 The '806 patent
discloses aims for future treatment of diseases via transplantation of HESC-derived

cells. 104
Finally, the '913 patent is a continuation of the '806 patent and claims the
advantageous maintenance of HESCs without the addition of anti-differentiation
media.105
Simply put, this invention illustrates a novel characteristic of these
10 6
primate ES cells and provides a new method of HESC maintenance.

3. Analysis of the WARFAgainst the Prior Art PatentsBelies Obviousness
A first patent examiner rejected each of the pioneering WARF '780 patent
claims. The second and third patent examiners rejected the claims of the '806 patent
and the '913 patent, respectively. The approach in these two subsequent rejections
parallel the grounds for rejecting the '780 patent. One common theme presented and
relied on by the examiners was the ease with which the prior art would extend to
other species, especially humans. The claims of the '780 patent may fall under the
literal interpretation of the prior art patents. However, the literal extension does a
distinct injustice to the innovative elements of the WARF patents. For example, the
examiner states that the '065 patent "teaches" the isolation and maintenance of
"animal" embryonic cells and correlates this to primates/humans. 10 7 The examiner
also unfairly extends the maintenance of embryonic stem cells of the '065 from the
108
specified "about 20 weeks" to cells "capable" of proliferation of over one year.
Similarly, the examiner rejects the claims of the '780 patent in light of the '926
patent by extending "at least 20 passages" to "capable of indefinite maintenance."' 10 9
Further, the examiner focuses on the unpatentable inherent properties of embryonic
stem cells; however, the claims of the patent are for "a purified preparation of
primate embryonic stem cells" and this "preparation" differs greatly from naturally

101 Id. at col.4; see also Bongso et al., supra note 90, at 2110 (reporting that in the only
published report on attempts to isolate HESCs, conditions were used (LIF in the absence of
fibroblast feeder layers) that did not result in HESCs which can remain in an undifferentiated state
and failed to continue to proliferate after 1 or 2 subcultures).
102 Primate Embryonic Stem Cells, U.S. Patent No. 6,200,806 (filed June 26, 1998).
103 Id. at col.21.
104 Id. at col.16-17 (explaining human diseases potentially treatable with HESCs include
neurological disorders such as Parkinson's disease, juvenile onset diabetes or AIDS, and because
undifferentiated ES cells can proliferate indefinitely in vitro they can be genetically manipulated
either to prevent immune rejection after transplantation, or to give them new genetic properties to
combat specific diseases).
1051
Primate Embryonic Stem Cells, U.S. Patent No. 7,029,913 (filed Oct. 18, 2001).
106 Id. at col.21-22 (declaring cell culture of the HESCs no longer requires exogenous addition
of leukemia inhibitory factor to maintain the cells in an undifferentiated state).
107 PONNALURI, supra note 66, at 10.
108 Id.
109 Id.at 13, 15.
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occurring embryonic stem cells. 110 HESCs do not inherently grow in vitro; nor do
HESCs inherently proliferate in an undifferentiated state.
The examiner rejected the method claims of the '780 patent that detailed the
isolation of the primate embryonic stem cells. 1 1 The examiner used each prior art
112
reference available to show the methods were similar or "the exact same method."
These arguments may have merit and WARF may have to consider an amendment
concerning these claims. Importantly, the method claims of the '780 patent would
not dampen the true innovative establishment of immortal HESCs, namely the
inventive creation of cell culture conditions sufficiently mimicking the growth
113
conditions of the primate body.
Embryonic stem cell science at the time of the invention was shackled with
considerable unpredictability, particularly in regards to any methods in human
research. The prior art references disclose research methodologies in embryonic stem
cell science and mention the desire to extend the science to humans. However, in
view of the state of the art at the time, the extensions towards HESC creation were
more likely classified as "merely invitations to those skilled in the art to try to make
the claimed invention" or "obvious to try."114 This "obvious to try" notion is not a
permissible grounds for rejection of a patent as obvious.115 Additionally, when an
invention was "obvious to try" following the disclosure of a new technology or
methodology related to a new area of research, the invention may be considered
116
nonobvious if the prior art only revealed generalities towards the result.
Those skilled in the art of embryonic stem cell science, at the time of the
invention, possessed extraordinary scientific abilities necessary for the cutting edge
area of technology. However, obviousness is not determined from the views of these
specialists or the patentee.1 17 Obviousness analysis is viewed in terms of one having
ordinaryskill in the art. 118 Also, only a reasonable expectation of success from the
combination of prior art is required to find an invention obvious.1 19 When viewing
the prior art, there is considerable evidence that one of ordinary skill in the art would
not be able to easily, or reasonably, generate HESCs from the combined teachings of
the prior art. The previously considered Piedrahita reference exemplifies this by
disclosing a complete failure in establishing embryonic stem cells from sheep using

110
Id.at 3-6.
'' 'Id. at 17-19.
112 Id.
113CHRISTOPHER THOMAS SCOTT, STEM CELL Now: FROM THE EXPERIMENT THAT SHOOK THE

(2006) (describing the replication of the in 7ivo growth
environment as the first major groundbreaking hurdle).
114 In -rePatrick H. O'Farrell, 853 F.2d 894, 902 (Fed. Cir. 1988).
115Id.("Any invention that would in fact have been obvious under § 103 would have also have
been, in a sense, obvious to try.").
116Id. at 903; see also In re Dow Chemical Co., 837 F.2d 469, 473 (Fed. Cir. 1988).
117
Standard Oil Co. v. Am. Cyanamid Co., 774 F.2d 448 (Fed. Cir. 1985) (O]ne should not go
about determining obviousness under § 103 by inquiring into what patentees (i.e., inventors) would
have known or would likely have done, faced with the revelations of references.").
118 35 U.S.C. § 103(a) (2006).
119 -In -re O'Farrell, 853 F.2d 894, 903-04 (Fed. Cir. 1988) (noting that inventions might seem
obvious on the surface, but the actual reduction to practice is more telling because there are always
unexpected results or delays).
WORLD TO THE NEW POLITICS OF LIFE 2
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the same methods successful in mice. 120 Moreover, the Bongso reference isolated
HESCs but could not maintain these cells for over two passages. 121 In fact, the
122
maintenance of HESCs requires a complex solution of nutrients and growth media.
More telling, present research still holds that "[hiuman embryonic stem cells are
123
notoriously difficult to handle."
When compared, the WARF patents do not describe inventions obvious or
anticipated in light of the prior art submitted by FTCR and PUBPAT. The prior art
lacks any teaching for the creation HESCs; only teaches isolation of mouse or pig ES
cells; and with a few keystrokes, suggests application of this groundbreaking,
complex methodology in humans. 24 It is often found in research that what works in
animals may not always translate to humans.1 25 The prior art recites species-specific
isolation procedures, but does not follow up with future implications for human
cells.1 26 Importantly, none of the references taught a protocol for maintenance of
HESCs. Even though human welfare is usually an implicit motivation in scientific
studies, the simple broadening of a particular invention in the claim language to
encompass a complex human-based undertaking should not be enough to satisfy the
requirements for finding an invention obvious in light of a combination of prior art
references.

4 The SecondaryFactorsalso FavorNonobviousness
The secondary factors of nonobviousness, although not determinative, support
the alternative considerations for the ultimate ascertainment of nonobviousness of an
invention. 127 These secondary factors may compromise: (1) evidence of copying; (2) a
long-felt, but unmet need; (3) the failure of others; (4) commercial success; (5)
unexpected results from the claimed invention; (6) unexpected properties of the
claimed invention; (7) licenses of the invention; and (8) skepticism of those skilled in
128
the art before the invention.

120Piedrahita supranote

64.

121Bongso
122

et al., supra note 94, at 2110.
MELISSA K. CARPENTER et al., Protocols for the Isolation and Maintenance of Human

Embryonic Stem Cells, in HuMAN EMBRYONIC STEM CELLS 116-120 (Totowa NJ: Humana Press, A.
Y. Chiu and M. S. Rao, eds., 2003).
123 Gareth Cook, US. Stem Cell Research Lagging Without Aid, Work Moving Overseas,
BOSTON GLOBE, May 23, 2004, Al. "A lot of stem cell biology is like gardening, [s]ome people can
grow orchids, and some can't grow tomatoes." Id. (quoting Stephen Minger, who isolated the cystic
fibrosis cell line and is an American scientist who now works at King's College London).
124 See In
Vitro Propagation of Embryonic Stem Cells, U.S. Patent No. 5,166,065; see
ROBERTSON ET AL. II, supra note 63; see ROBERTSON ET AL. I, supra note 62; see Piedrahita, supra
note 64.
125 Stephen S. Hall, Adult Stem Cells: With Research on Embryonic Stem Cells Mired in
Controversy,Adult Stem Cells are Quietly Providing the Basis for Striking Advances Toward New
Therapies, TECHN. REV., Nov. 2001, at 2 (detailing intriguing findings of neural cell growth from
stem cells in mice, but noting the experiments are far from definitive).
126 See '065 Patent; see ROBERTSON ET AL. I, supra note 62; see ROBERTSON ET AL. 11, supra
note 63; see Piedrahita, supra note 64.
127 Richardson-Vicks, Inc. v. Upjohn Co., 122 F.3d 1476, 1483 (Fed. Cir. 1997).
128 Amgen, Inc. v. Hoescht Marion Roussel, Inc., 126 F. Supp. 2d 69, 113 (D. Mass. 2001).
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The inclusion of the evidence supporting the secondary factors also precludes a
finding of obviousness for the WARF patents. It was well recognized that the
invention was the first evidence disclosing the creation of viable embryonic stem cell
lines. 129 Specifically, the patent declares that the creation of immortal primate
embryonic stem cell lines had never been accomplished before. 130 Similarly, the
development of ES cells and HESCs that remain undifferentiated and continue to
replicate forever were unexpected inventions definitely not anticipated by the others
skilled in the art at the time of the WARF patents. 131 The span of fifteen years from
Robertson '83 to the first WARF patent only highlights the innovation, or long-felt
need, behind the patents. Stated another way, as no one was able to extend any
previously available isolation procedures into isolation of HESCs for such a period of
time, an argument stating that HESC science was obvious contradicts the actual
progression of embryonic stem cell science. Additionally, the great number of
licensees of the HESC technology in this highly technical area of research also
indicates commercial success and a validation of the innovative characteristics of the
HESCs. 132 The inclusion of the secondary factors involved with the WARF patents
only strengthens the preceding arguments of nonobviousness.
Overall, WARF should prevail when the PTO considers its response. The PTO
concedes that it "does not have the facilities or resources to provide factual evidence
needed" for a proper comparison. 133 The PTO simply shifts the burden to WARF
after the preliminary finding of obviousness. 134 For WARF, these issues were fought
135
over during the initial patent prosecution, so "[there's really nothing new here."

5. WARF is not Without Alternative Options
WARF will rebut the results of this reexamination by clearly pointing out why
the subject matter as claimed is not anticipated or rendered obvious by the prior
art.136 Additionally, if necessary, the reexamination procedure allows the patent
owner an opportunity to propose any amendment or narrow the scope of the patent

129 E.g., Thomas H. Maugh II, Scientists Move Closer to Ability to Grow Tissue Research: Cell
Reproduction Technique Holds Potential for Producing Organs for Transplant, L.A. TIMES, Nov. 6,
1998, at 1.
1:30
'780 Patent.
131 Cathy Tran, WARE Stem Cell Patents Challenged, SCIENTIST, available at
http://www.thescientist.com/news/home/25037/ (last visited Apr. 19, 2007). "From firsthand painful
experience, [the techniques were] not obvious in the scientific community . . .is easy in retrospect,
but you really have to base it on real firsthand experiences of the people in those days." Id. (quoting
one of the groups that tried and failed to isolate HESCs, researcher Michael West, CEO of Advanced
Cell Technology and founder of Geron Corporation).
132 Wahlberg, supranote 46.
133 PONNALURI, supra note 66, at 15.
134 Id.
135

John Schmid, Stem -Cell Patents Tossed: Preliminary Decision Against UW May Set Up

Years -LongBattle, MILWAUKEE

J. SENTINEL, Apr. 2,

136 37 C.F.R. § 1.530(c) (2000).

2007.
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claims to avoid the newly proffered prior art. 137 Finally, a patent owner is also
138
entitled to seek court review with respect to a decision of unpatentablility.
One of the chief avenues WARF may tackle is the enablement issue in the prior
art. Patents issued are presumed to have satisfied the statutory requirement of
enablement. 13 9 Normally, a prior art reference must be enabling to satisfy a full
disclosure of the invention to the public. 140 However, during this reexamination, the
enablement considerations of the prior art were held to a lower requirement than the
enablement necessary under statutory analysis of a patent.1 41 Neither the '065 or
'926 patents teach a specific method for isolation and maintenance of HESCs even
though these cells do fall under their respective claims. 1 42 Therefore, WARF is
challenged with the burden of showing that the mere suggestion of extending the
claimed methods of embryonic stem cell isolation and maintenance in the '065 and
'926 patents to humans was not sufficiently taught, or enabled, by the
specifications. 143 Some of the previously stated points will bolster this enablement
argument in favor of WARF; notably, the span of time between the '065 patent and
the first WARF patent, and the difficulty in isolating and maintaining an immortal
HESC line will diminish the legitimacy of the suggestions in the prior art.

C. Are the Royalties for WARF's PatentsExcessive?
The attacks on the validity of the WARF patents have also included
deliberations on the patent royalties levied by WARF on any entity that uses its
inventions in a commercial setting.1 44 The opponents argue that the royalties are
145
excessive and are driving both money and research out of the United States.

137 35 U.S.C. § 305 (2006) C[T]he patent owner will be permitted to propose any amendment to
his patent and a new claim or claims thereto, in order to distinguish the invention as claimed from
the prior art ... or in response to a decision adverse to patentability."); see, e.g., Total Containment,
Inc. v. Environ Products, Inc., 921 F. Supp. 1355, 1378-79 (E.D. Pa. 1995), affirmed in part,vacated
in part,106 F.3d 427 (Fed. Cir. 1997) (explaining that the statute does not allow the patent owner to
expand the scope of the claims as this can only be done by patent reissue).
138 35 U.S.C. § 306 (2006) ("[P]atent owner involved in a reexamination ... may appeal under
the provisions of section 134 of this title, and may seek court review ... with respect to any decision
adverse to the patentability of any original or proposed amended or new claim of the patent.").
139 Amgen, Inc. v. Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1354 (Fed. Cir. 2003).
140
Amgen, Inc. v. Hoescht Marion Roussel, Inc., 126 F. Supp. 2d 69, 114 (D. Mass. 2001).
111CELSA, supranote 66, at 9.
142 See In Vitro Propagation of Embryonic Stem Cells, U.S. Patent 5,166,065; Pluripotential
Embryonic Cells and Methods of Making the Same, U.S. Patent No. 5,690,926.
"13 Amgen, 314 F.3d at 1354-55.
144 See Steven Ertelt, Patent Debate Stalling Stem Cell Research More Than PresidentBush
Veto, http://www.lifenews.com/bio1657.html (last visited Apr. 19, 2007). "The patents are impeding
our research .. .it is making scientists go overseas to do this sort of research. It isn't the funding
that's sending us overseas. It's the patent issues." Td.
145 Id. (explaining that the licenses for the embryonic stem cells are not difficult to obtain, but
the costs may be $75,000-$250,000 for the biotech firms hoping to initiate stem cell research).
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WARF counters that it is a necessary right of the patentee to assess royalties that
146
may be used to fund its future research and promote scientific progress.
"The applicant, patentee, or his assigns or legal representatives may ... grant
and convey an exclusive right under his application for patent, or patents, to the
whole or any specified part of the United States." 147 Furthermore, a patentee may
also refuse to grant anyone a patent license altogether. 148 Any motive for refusing to
offer licenses, valid or otherwise, is of no consequence.1 49 Thus, the long-standing law
grants the inventor absolute property rights in his invention.1 50 Unsurprisingly, the
courts have thus held that a patentee is free to set any royalty for their patented
product.1 51 In contrast to these foundational rules of the patent monopoly, there has
been the rare occasion for the court to hold, where a patent owner controls a major
portion of an industry, the imposition of exorbitant and oppressive royalties may
detrimentally affect public interests. 152 The actions of WARF in the HESC research
community do not rise to these exceptional levels.
Recent trends have alluded to an initial exodus of money and research in stem
cell science. 153 This is likely a response to the aforementioned lack of federal funding
in stem cell research. Others distinctly blame the loss on the excessive royalties and
the uncertainty any entity would face if it brought a stem cell-related product to the
commercial market.1 54 Yet, WARF cheaply distributes HESCs to hundreds of
researchers around the world. 155 If these recipients strive to make money off the
innovation of WARF, it is only just that WARF also benefit in order to bolster its own
116 California Stem Cell Report, supra note 53 (noting that WARF would not allow CIRM to
"trade on Wisconsin technology to build a commercial program" and that Wisconsin was entitled to
receive payments for use of its products and that the funds would go for research and education).

17

35 U.S.C. § 261 (2006).

35 U.S.C. § 271(d)(4) (2006) (explaining that the patent statute provides that no patent
owner otherwise entitled to relief for infringement or contributory infringement of a patent shall be
denied relief or deemed guilty of misuse or illegal extension of the patent right by reason of his
having refused to license or to use any rights to the patent); see SCM Corp. v. Xerox Corp., 645 F.2d
1195, 1206 (2d Cir. 1981) (explaining that the threat of treble damages liability for refusing to
license might inhibit potential patent holders from disclosing patents for commercial exploitation,
and the efficacy of the economic incentives afforded by our patent system might be severely
diminished).
'19 Radio Corp. of Am. v. Hygrade Sylvania Corp., 10 F. Supp. 879, 883 (D.N.J. 1934).
150 Id. (explaining that if the court held the power to compel the patentee to license its
invention the rights of the patent owner and the patent itself would be worthless).
151 W.L. Gore & Assocs. v. Carlisle Corp., 529 F.2d 614, 623 (3d Cir. 1976) (stating that a price
"so high as to preclude acceptance of a license offer is, after all, not appreciably different from a
refusal to license upon any terms."); see Brulotte v. Thys Co., 379 U.S. 29, 33 (1964) ('A patent
empowers the owner to exact royalties as high as he can negotiate with the leverage of that
monopoly.").
152 Am. Photocopy Equip. Co. v. Rovico, Inc., 359 F.2d 745, 748 (7th Cir. 1966) (finding the
oppressive royalties, control of an industry, and price fixing of a plaintiff warrants relief to a
defendant in a preliminary injunction motion). But ef Standard Oil Co., Inc. v. United States, 283
U.S. 163, 170 (1931) (holding that a patent pool had no obligation to charge a reasonable royalty).
153 Cook, supra note 122, at Al (noting that stem cell companies are moving overseas due to
better funding policies). The United States is losing its competitive edge as other countries are
producing their own HESCs. Id.
154 Posting of Kapor, supra note 33 (explaining terms under which the state would benefit and
the taxpayers repaid in the event of successful commercialization are murky and lack sufficient
protection for the public).
155 WiCell, supra note 49.
148
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scientific output. WARF has disclosed its invention to all and has earned its patent
monopoly. Perhaps due to the outside influences described herein, the boundaries of
this monopoly, specifically the scope of the claims or extent of the royalties, may be
altered in a more stem cell-friendly governmental environment. Until then, the stem
cell patent royalties levied by WARF should not be judged excessive.

III. PROPOSAL
Pioneering work may become a target in any industry following an award of a
patent monopoly. Therefore, this section recommends guidelines and legislation to
protect the valid interests of the stem cell pioneers. First, adherence to the policy of
patent protection for revolutionary inventions must occur to "promote the useful
arts." Second, patent reform proposing post-grant opposition procedures will reduce
later conflict against pioneering patents. Last, a perceived trend of the courts
towards compulsory licensing must be resisted.

A. The Incentive to Innovate Should Be Protected
"[Tihe idea that exclusive rights in new knowledge will promote scientific
progress is counterintuitive to many observers of research science, who believe that
science advances most rapidly when the community enjoys free access to new
discoveries." 156
However, courts have upheld the Constitutional purpose of
promoting the sciences by enforcing patent monopolies, thereby inducing the
incentive to research new inventions, in exchange for disclosure of the invention to
the public. 157 The disclosure enables those "skilled in the art" to make and use the
158
invention to further science and the useful arts.
Without incentive provided by patent protection, fewer inventions will be made
and disclosed if others can simply use novel discoveries without sharing in the
costs. 159 This is especially pertinent in biotechnology where commercial interests in
academic biomedical research have gathered momentum. 160 Academic institutions
are generally not equipped to manufacture and distribute products, and they
typically license the patented innovations to the commercial interests. 161 Proper
patent protection allows for correlative royalties awarding the institution for its

156 See Rebecca S. Eisenberg, Patents and the Progress of Science.* Exclusive Rights and
Experimental Use, 56 U. CHI. L. REV. 1017, 1017 (1989).
157 Kewanee Oil Co. v Bicron, 416 U.S. 470, 480-81 (1974) (noting that the stated objective of
the Constitution in granting power to Congress to legislate in the area of intellectual property is to
promote the progress of science and useful Arts by offering a right of exclusion for a limited period
as an incentive to inventors to risk the often enormous costs of time, research, and development).

158 35 U.S.C. § 112

1 (2006).

1519See Eisenberg,

supra note 156, at 1025-26 (explaining that if others freely exploited
patents, prices would fall and the patent owners would get diminishing returns on their hard earned
inventions).
160 Seo id.at 1018.

161 Rebecca S. Eisenberg, Public Research and Private Development: Patents and Technology
Transfer in Government-SponsoredResearch, 82 VA. L. REV. 1663, 1698 (1996).
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discoveries and providing funding for future research. 162 WARF is entitled to its
royalties benefit and should not be penalized because of the pioneering nature of its
invention.
However, a stronger patent protection policy may have a detrimental effect on
the benefit to competitors. 163 Competitors may face increased costs, difficulties in

164
trying to circumvent patented technologies, and the risk of infringement lawsuits.

Therefore, an important factor in the counterbalance of the patent protection and
rights is the limited term of the patent. 165 The WARF patents will persist until at
least 2015.166 This period may seem extensive. Yet, in the adolescent field of stem
cell science, the patent term is constructively reduced in duration as commercial
discoveries often endure a prolonged path to the market. 167 As such, WARF is only
more justified in benefiting monetarily from its labor to augment its own incentive to
continue to innovate.

B. Support for The PatentReform Act Will Aid Patent Validity
Legislators have already begun to attempt to reform the patent opposition
process. For instance, the House of Representatives has proposed "The Patent
Reform Act" ("the Act") that contains a section detailing post-grant opposition
proceedings. 168 Under the Act, a non-owner of a patent may file a petition to institute
a proceeding to cancel patent claims the petitioner believes to be invalid. 169 The Act
limits the opposition request to twelve months after the grant of a patent. 170 During
the twelve-month period, the opposition must provide the issues against the patent
claims with particularity, allowing the patentee to respond to, amend, or add claims
during the proceedings. 171 The determination of the post-grant opposition concludes
with certification that denies an opposer the opportunity to raise the issue again
172
before the PTO or the courts.
162 See WILLIAM M. LANDES & RICHARD A. POSNER, THE ECONOMIC STRUCTURE OF
INTELLECTUAL PROPERTY LAW 300 (2003).
103 Soo id. at 297-300 (analyzing the marginal costs of competitors versus residual demand
that results in a higher share of the market for a patentee).
104

See id.at 299.

1 5 See 35 U.S.C. § 154 (2006).
166 See Primate Embryonic Stem Cells, U.S. Patent No. 5,843,780 (filed Jan. 18, 1996 but
claiming, as a continuation-in-part application, the priority date of Jan. 20, 1995 from a previous
abandoned application); see Primate Embryonic Stem Cells, U.S. Patent No. 6,200,806 (filed June
26, 1998, and also claiming the Jan. 20, 1995, priority date); see Primate Embryonic Stem Cells,
U.S. Patent No. 7,029,913 (filed Oct. 18, 2001, and also claiming the Jan. 20, 1995, priority date).
107 Edmund W. Kitch, The Nature and Function of the Patent System, 20 J.L. & ECON. 265,
266-68 (1977) (explaining the "prospect theory" in which early grants for patents not yet
commercially viable actually benefits society by reducing wasteful duplicative efforts by
competitors).
168 Patent Reform Act of 2007, H.R. 1908, 110th Cong. (2007) (introduced to amend title 35,
United States Code, relating to the procurement, enforcement, and validity of patents).
169
Id. § 321.
170 Id.§ 322.
171 Id. §§ 324, 325 ("The party advancing a proposition under this chapter shall have the
burden of proving that proposition by a preponderance of the evidence.").
172 Id.§§ 333, 334.
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The Senate proposal offered is substantively similar to the House's proposed
Act.173 The filing period is also twelve months after the grant of the patent 174 and a
second window is available if the petitioner "establishes a substantial reason to
believe that the continued existence of the challenged claim in the petition causes or
is likely to cause significant economic harm," the petitioner has been notified of
75
alleged infringement, or if the patentee consents to the proceeding.
This legislative reform effort aims to improve public confidence in the validity
and quality of issued patents. The legislation will allow the PTO to bolster its own
asset of trained professionals in the sciences and patentability requirements with
knowledgeable persons timely filing challenges to a patent's validity.1 76 Further, the
legislative efforts hope to diminish the amount of subsequent litigation that diverts
money and resources from more productive purposes, purposes such as promoting
innovation and commercializing inventions. 177 Litigation costs have skyrocketed,
averaging $1.5 million to $4 million per party, depending on the scope of the
technology. 178 A comprehensive post-grant review process for patents may alleviate
this drain and protect society and patentees alike. 179 Specifically, the legislation
would validate issued patents and prevent harassment of patent owners after patent
issuance.180
The stem cell patents could have benefited from this proposed legislation.
Foremost, the time limits for post-grant review would have brought challenges to
validity immediately. Thus, WARF could have profited from the patent's innovation
at the time of issuance without the problematic hindsight of later patent
reexaminations. Future disputes similar to the present stem cell patent challenge
may be averted if this legislation is enacted. Moreover, societal trust in the patent
system will strengthen and costs associated to questionable patents will be reduced.

173 Patent Reform Act of 2007, S. 1145, 110th Cong. (2007) (describing a robust post-grant
opposition system for challenging the validity of problematic or suspect patents in an administrative
proceeding instead of waiting to assert invalidity as a defense in an infringement action).
174 Id. § 322.

175Id.

Patent QualityImprovement.*Post-Grant Opposition HearingBefore Subcomm. on Courts,
the Internet,and IntellectualProperty, Comm. on the Judiciary,108th Cong 18 (2004) (noting that
the PTO can decrease the rate of litigation by using its own professionals with scientific or technical
expertise in the field of the invention in addition to agents intimately familiar with the application
of certain of the patentability requirements: novelty, nonobviousness, written description,
enablement and utility for these post-grant reviews).
177 Id.at 7 (2004) (statement of Lamar Smith, Chairman, Subcomm. On Courts, the Internet,
and Intellectual Property).
178Id. at 32.
179 See id. at 15 (stating that the review procedure is "designed to be more efficient than
litigation while preserving enough of the full participation according to parties in litigation that
challengers will be able to risk being able to be bound by the result").
180 Id. at 18 (declaring that frivolous challenges would tie up a patent in a long and endless
administrative proceeding and be just as detrimental to the patent users, the community, and the
needs of the public).
176
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C. Compulsory Licensing Should Be Avoided
The opposition to the stem cell patents believes the monopolistic power of patent
holders is waning. 181 The landmark eBay, Inc. v. MereExchange,L.L. C18 2 decision is
thought to weaken the rights of the patent holder by refusing to automatically grant
a permanent injunction against an infringer.183 The Supreme Court opted against
the Federal Circuit's general rule for permanent injunctions barring exceptional
circumstances and utilized the traditional factors for an equitable decision on the
need for an injunction.18 4 Importantly, the Court noted that the patentee might not
be allowed its right to exclude despite willful infringement by eBay. l8 5 Those
favorable to the inventors or patentees believe the holding of this case amounts to a
compulsory license in favor of potential infringers. 1 6 The patent holder has lost itS
bargaining power of injunction, and any judicial outcome between the parties will
only result in royalties under the discretion of the courts.18 7 Accordingly, the stem
cell patent opposition believes this result will open the gateway to sanctioned use, at
a judicially created price, of the stem cell patents for the betterment of society and
18 8
the benefit of those in need of the therapeutic technology.
Compulsory licensing is not commonplace and is heavily disfavored in the patent
system.18 9 In fact, it has only been granted in narrow cases presenting a strong
countervailing public interest, 190 or in cases brought by the government as a remedy
181 Foundation for Taxpayer and Consumer Rights, Supreme Court's eBay Ruling Weakens
Position of Stem Cell Patent Holder But Vital California Research Still Impeded Consumer
Advocates Say, May 18, 2006, available athttp://www.consumerwatchdog.org/healthcare/pr/?postld
=6256 (last visited Apr. 19, 2007).
182 126 S. Ct. 1837 (2006).
183 Foundation, supranote 180.
184 eBay, 126 S. Ct. at 1839 (providing the factors that a plaintiff must demonstrate for an
injunction as: (1) that it has suffered an irreparable injury; (2) that remedies available at law, such
as monetary damages, are inadequate to compensate for that injury; (3) that, considering the
balance of hardships between the plaintiff and defendant, a remedy in equity is warranted; and (4)
that the public interest would not be disserved by a permanent injunction).
185 Id. at 1841 (noting the difficulty of equating the right to exclude with monetary damages).
186 Anne Broache, Supreme Court Rules in Favor of eBay, NEWS.COM, May 15, 2006,
http ://news.com.com/Supreme+Court+rules+in+favor+of+eBay/2100-1030_3-6072150.html
(last
visited Apr. 19, 2007).
Without injunctions as leverage, inventors may only be entitled to receive monetary damages
from any infringement proceeding-this "amounts to a compulsory license at the whim of a judge."
Id. (quoting Ronald Riley, president of the Professional Inventors Alliance, which advocates for
independent inventors and small- and medium-size businesses).
187See id.
188 See Foundation, supra note 180 (explaining that patent holders, like WARF, may find it
more difficult to prove that an injunction is necessary under the new guidelines established by
eBay).
189 See, e.g., Dawson Chem. Co. v. Rohm & Haas Co., 448 U.S. 176, 186 (1980) ("Compulsory
licensing is a rarity in our patent system, and we decline to manufacture such a requirement out of
[the patent statute].").
190 See 28 U.S.C. § 1498 (2006) (allowing a patent owner to sue for reasonable and entire
compensation in the Court of Federal Claims when the federal government manufactures or uses a
patented invention without a license); 42 U.S.C. § 2183(a) (2006) (subjecting certain kinds of patents
relating to nuclear energy to licensing by the Nuclear Regulatory Commission following notice to the
patent-holder and a hearing); 7 U.S.C. § 2404 (2006) (subjecting certain plant varieties to a two-year
compulsory license when the Secretary of Agriculture finds it "necessary in order to insure an
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for monopolistic restrictions or pricing. 191 It is alleged that the implementation of
compulsory licensing would lead to a "regime of routine infringement-and therefore
routine litigation" between parties at odds over a patent technology. 192 The influx of
infringement would in turn diminish the value of patents and negatively effect
193
innovation normally protected by infringement lawsuits and injunctions.
The policy against compulsory licenses also survives challenges to excessive
royalties. 194 The "imposition on a patent owner who would not have licensed his
invention for a given royalty is a form of compulsory license, against the will and
interest of the person wronged, in favor of the wrongdoer."1 95 Furthermore, the
1 96
courts do not require a licensee to even make a profit in the license negotiation.
These principles, as they pertain to infringers, do not favor those praying for
compulsory license on the grounds of excessive royalties.
This precedent suggests the courts are reticent to apply compulsory licenses at
all and the royalties imposed by WARF on private research entities are not likely to
be deemed overly excessive. The government should thus uphold these well-reasoned
policies against compulsory licensing and protect patentee's rights barring an
1 97
exceptional circumstance.

IV. CONCLUSION

Human embryonic stem cells are a true innovation full of promise for the
scientific and therapeutic community. The myriad of possibilities inherent in these
cells is yet to be determined. WARF has enabled the scientific community in this
regard by providing HESCs at a minimal cost to basic science researchers. However,
WARF levies a royalty on any entity utilizing WARF's patents in a commercial
fashion in order to fund WARF's own future research. Now, with the benefit of
hindsight, interest groups are challenging the validity of the WARF's patents.
Furthermore, an outcry from these same interest groups has arisen over "stifling"
royalties. These charges oppose the practice of the PTO and the rights of patent
ownership. In the end, the innovation behind the WARF stem cell patents must be
adequate supply of fiber, food, or feed in this country," with the remuneration a reasonable royalty,
or greater if litigation is necessary to collect).
191 E.g, Hartford-Empire Co. v. United States, 323 U.S. 386, 419 (1945) (enforcing compulsory
licensing when defendants cooperated in obtaining and licensing patents, limited and restricted the
use of the patented machinery by a network of agreements, and illegally set prices).
192 Brief of Rembrandt IP Management, L.L.C. as Amicus Curiae in Support of Respondent at
15, eBay, Inc. v. MercExhcange, L.L.C., 126 S. Ct. 1837 (2006) (No. 05-130) (arguing that companies
may forego a license because infringement, litigation, and payment of damages may be a better
business decision under the new injunction guidelines for patents).
19:3 See F. Scott Kieff, Property Rights and Property Rules for CommercializingInventions, 85
MINN. L. REV. 697, 733-35 (2001).
194 Soo, e.g., Monsanto Co. v. Ralph, 382 F.3d 1374, 1384 (Fed. Cir. 2004).
195 Del Mar Avionics, Inc. v. Quinton Instrument Co., 836 F.2d 1320, 1328 (Fed. Cir. 1987).
196 Monsanto, 382 F.3d at 1384.
197 Public Health Emergency Medicines Act, H.R. 4131, 109th Cong. (2006) (stating that "In the
case of any invention relating to health care the Secretary of Health and Human Services shall have
the right to authorize use of the subject matter of the patent without authorization of the patent
holder ... ").
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recognized, as it was at the time of discovery. The royalties charged by WARF are
equally just and illustrate the use of the patent right to further stimulate innovative
discovery. To find any different would weaken the patent system and restrain the
progress of the sciences.

